AI assistant
Anteris Technologies Global Corp. — Board/Management Information 2016
Feb 7, 2016
33869_rns_2016-02-07_74b49e1e-5a50-467d-91ac-db71bf7f4d10.pdf
Board/Management Information
Open in viewerOpens in your device viewer
Admedus Ltd ABN 35 088 221 078
==> picture [226 x 82] intentionally omitted <==
REGISTERED OFFICE: 26 Harris Road Malaga Western Australia 6090
ASX ANNOUNCEMENT
PO Box 6879 East Perth Western Australia 6892 T +61 (0)8 9266 0100 F +61 (0)8 9266 0199 E [email protected]
ADMEDUS DIRECTOR STEPS DOWN
- Peter Turvey steps down from board
Brisbane, Australia 8 February 2016
Admedus Limited (ASX: AHZ) today announced that Mr Peter Turvey has resigned as an independent Non-Executive Director due to other commitments. Mr Turvey has served on the Admedus board for the past 3 years and was head of the Audit and Risk Committee.
“We thank Peter for his invaluable contribution over the past 3 years. During this period Admedus has grown through its R&D programs, approval of the lead regenerative product CardioCel[®] and the progression of the immunotherapies program into the clinic” stated Admedus CEO Mr Lee Rodne
Mr Turvey’s resignation is effective immediately.
Follow us: Twitter: @Admedus Facebook: www.facebook.com/pages/Admedus
For more information, please contact:
Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100
Media :
Shevaun Cooper | PR Manager | Admedus Limited Tel: +61 (0) 417 985 599 | Email: [email protected]
Media Europe
FTI Consulting Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000 [email protected]
US Investor
Rx Communications Group, LLC Melody A. Carey +1 917 322 2571 [email protected]
==> picture [595 x 44] intentionally omitted <==
==> picture [170 x 63] intentionally omitted <==
About Admedus Limited
Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the company can be found on www.admedus.com